Abstract: A hearing apparatus that processes an audio signal by adaptive filtering operates efficiently. The hearing apparatus has a first stage transformation unit and at least two second stage transformation units. Each of the second stage transformation units splits the signal of one of the first stage channels through transformation onto sub-channels of the channel. A filter unit in each channel that has a second stage transformation unit filters the signal of the channel depending on weighting factors that are determined in each case for the sub-channels. The filter units are configured to exchange weighting factors among themselves, which means that only some of the weighting factors actually need to be calculated.

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.

Abstract: The invention relates to novel oxazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.

Abstract: A filter bank with a sufficiently high resolution for amplification and noise reduction and with the lowest possible computational complexity is provided for a hearing device and, in particular, for a hearing aid. Two-stage frequency transformation with little latency is therefore proposed for hearing aids. Some of the processing, for example the amplification, is carried out after high stopband attenuation in the first stage. An increased frequency resolution is achieved in a second stage before the back-transformation in the first stage, which is favorable for noise reduction, for example.

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.

Abstract: A smoothing method for suppressing fluctuating artifacts in the reduction of interference noise includes the following steps: providing short-term spectra for a sequence of signal frames, transforming each short-term spectrum by way of a forward transformation which describes the short-term spectrum using transformation coefficients that represent the short-term spectrum subdivided into its coarse and fine structures; smoothing the transformation coefficients with the respective same coefficient indices by combining at least two successive transformed short-term spectra; and transforming the smoothed transformation coefficients into smoothed short-term spectra by way of a backward transformation.

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.

Abstract: The invention relates to novel heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free form or in pharmaceutically acceptable salt form, to their preparation, to their medical use and to medicaments comprising them.

Abstract: The invention relates to novel oxazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.

Abstract: The present application relates to foamable compositions and foams comprising stabilized chlorite, including stabilized chlorite solutions such as Oxovasin™, and to medical uses thereof, in particular for wound healing. The foamable compositions comprise at least one foaming agent, stabilized chlorite, water and optionally, a buffering agent.

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.

Abstract: A method for modification of a cepstro-temporally smoothed gain function of a gain function resulting in a bias compensated spectral gain function is provided. The cepstro-temporal smoothing increases the quality of an enhanced output signal, as it affects only spectral outliers caused by estimation errors, while the speech characteristics are well preserved. However, due to the cepstral transform, the temporal smoothing is done in the logarithmic domain rather than the linear domain, and hence results in a certain bias. Thus, the method for a general bias compensation for a cepstro-temporal smoothing of spectral filter gain functions that is only dependent on the lower limit of the spectral filter-gain function.

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of Alzheimer's Disease or diabetes via inhibition of BACE-1 or BACE-2.

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.

Abstract: A method for determining unbiased signal amplitude estimates () after cepstral variance modification of a discrete time domain signal (s(t)), wherein the cepstrally-modified spectral amplitudes () of the discrete time domain signal (s(t)) are ?-distributed with 2{tilde over (?)} degrees of freedom. A bias reduction factor (r) is determined using the equation r 2 = ? ? ~ ? ? ? ? ( ? ~ ) - ? ? ( ? ) , where 2? are the degrees of freedom of the ?-distributed spectral amplitudes of the discrete time domain signal (s(t)) and ? ? ( x ) = - 0.5772 - ? n = 0 ? ? ( 1 x + n - 1 1 + n ) ; then the unbiased signal amplitude estimates () are determined by multiplying the cepstrally-modified spectral amplitudes () with the bias reduction factor (r) according to the equation =r.

Abstract: A filter bank with a sufficiently high resolution for amplification and noise reduction and with the lowest possible computational complexity is provided for a hearing device and, in particular, for a hearing aid. Two-stage frequency transformation with little latency is therefore proposed for hearing aids. Some of the processing, for example the amplification, is carried out after high stopband attenuation in the first stage. An increased frequency resolution is achieved in a second stage before the back-transformation in the first stage, which is favorable for noise reduction, for example.

Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

Abstract: This invention relates to 4,4-disubstituted piperidine derivatives of the formula wherein A and R1 to R5 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.